Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: To determine the efficacy and toxicity of docetaxel as a thirdline therapy for patients with relapsed gastric cancer who have undergone modified oxaliplatin-fluorouracil (m-FOLFOX)-4 and modified irinotecan-fluorouracil (m-FOLFIRI) regimens. Methods: We analyzed 33 patients who had been histologically diagnosed with adenocarcinoma of the stomach and who had progressed after m-FOLFOX-4 and m-FOLFIRI regimens. Patients were treated with cycles of 75 mg/m2 docetaxel on day 1 every 3 weeks. Results: The median age of the patients was 56.0 years (range, 31.0 to 74.0), and 73% of the patients (24/33) had an Eastern Cooperative Oncology Group performance status of 0 or 1. All patients were evaluated in terms of tumor response:five (15%), nine (27%), and 19 (58%) patients experienced a partial response, stable disease, and progressive disease, respectively. The median time to progression was 2.1 months (95% confidence interval [CI], 1.63 to 2.58), and overall survival was 4.7 months (95% CI, 3.20 to 6.20), from the start of the docetaxel regimen. Assessing patients’ toxicity profiles, the median number of cycles was 2.0 (range, 1.0 to 12.0). The major hematologic toxicities included grade 3 to 4 neutropenia (19/33,58%), grade 3 to 4 thrombocytopenia (2/33, 6%), and grade 3 to 4 anemia (5/33, 15%). Neutropenic fever developed in three patients (3/33, 9%). The nonhematological toxicities were nausea and vomiting (10/33, 30%), abdominal pain (4/33, 12%), skin rash (1/33, 3%), and fluid retention (3/33, 9%). Conclusions: Docetaxel is a feasible third-line therapy regimen for patients with advanced gastric cancer after m-FOLFIRI and m-FOLFOX-4 regimens.
Abstract
Background/Aims: To determine the efficacy and toxicity of docetaxel as a thirdline therapy for patients with relapsed gastric cancer who have undergone modified oxaliplatin-fluorouracil (m-FOLFOX)-4 and modified irinotecan-fluorouracil (m-FOLFIRI) regimens. Methods: We analyzed 33 patients who had been histologically diagnosed with adenocarcinoma of the stomach and who had progressed after m-FOLFOX-4 and m-FOLFIRI regimens. Patients were treated with cycles of 75 mg/m2 docetaxel on day 1 every 3 weeks. Results: The median age of the patients was 56.0 years (range, 31.0 to 74.0), and 73% of the patients (24/33) had an Eastern Cooperative Oncology Group performance status of 0 or 1. All patients were evaluated in terms of tumor response:five (15%), nine (27%), and 19 (58%) patients experienced a partial response, stable disease, and progressive disease, respectively. The median time to progression was 2.1 months (95% confidence interval [CI], 1.63 to 2.58), and overall survival was 4.7 months (95% CI, 3.20 to 6.20), from the start of the docetaxel regimen. Assessing patients’ toxicity profiles, the median number of cycles was 2.0 (range, 1.0 to 12.0). The major hematologic toxicities included grade 3 to 4 neutropenia (19/33,58%), grade 3 to 4 thrombocytopenia (2/33, 6%), and grade 3 to 4 anemia (5/33, 15%). Neutropenic fever developed in three patients (3/33, 9%). The nonhematological toxicities were nausea and vomiting (10/33, 30%), abdominal pain (4/33, 12%), skin rash (1/33, 3%), and fluid retention (3/33, 9%). Conclusions: Docetaxel is a feasible third-line therapy regimen for patients with advanced gastric cancer after m-FOLFIRI and m-FOLFOX-4 regimens.
참고문헌 (20)
- Parkin DM, "Global cancer statistics", CA Cancer J Clin, 55, pp.74~108 (2005)
- Glimelius B, "Initial or delayed chemotherapy with best supportive care in advanced gastric cancer", Ann Oncol, 5, pp.189~190 (1994)
- Murad AM, "Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer", Cancer, 72, pp.37~41 (1993)
- Pyrhonen S, "Randomised comparison of f luorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer", Br J Cancer, 71, pp.587~591 (1995)
- Snyder JP, "The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density", Proc Natl Acad Sci U S A, 98, pp.5312~5316 (2001)
- Yvon AM, "Taxol suppresses dynamics of individual microtubules in living human tumor cells", Mol Biol Cell, 10, pp.947~959 (1999)
- Ajani JA, "Docetaxel for gastric and esophageal carcinomas", Oncology, 16(6), pp.89~96 (2002)
- Bang YJ, "Docetaxel 75 mg", m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial, 2002, pp.32, 248~254
- Giuliani F, "Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.)", Anticancer Res, 23(5), pp.4219~4222 (2003)
- Graziano F, "phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer", Ann Oncol, 11, pp.1263~1266 (2000)
- Lee JL, "A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy", Cancer Chemother Pharmacol, 61, pp.631~637 (2008)
- Taguchi T, "Late phase II clinical study of RP56976 (docetaxel) in patients with advanced", recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A), 1998, pp.25, 1915~1924
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Kim BG, "A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer", Am J Clin Oncol, 33, pp.246~250 (2010)
- Kim SG, "A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer", Jpn J Clin Oncol, 37, pp.744~749 (2007)
- Oh SY, "A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer", Acta Oncol, 46, pp.336~341 (2007)
- Sung-Hwan Suh, "Oxaliplatin with Biweekly Low Dose Leucovorin and Bolus and Continuous Infusion of 5-fluorouracil (Modified FOLFOX 4) as a Salvage Therapy for Patients w ith Advanced Gastric Cancer", Cancer Research and Treatment, 37(5), pp.279~283 (2005), 대한암학회
- Moon YW, "Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design", Cancer Chemother Pharmacol, 66, pp.797~805 (2010)
- Shimoyama R, "Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to f luorouracil, irinotecan, and cisplatin", Gastric Cancer, 12, pp.206~211 (2009)
- Kang JH, "Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone", J Clin Oncol, 30, pp.1513~1518 (2012)